Navigation Links
Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System

SUNNYVALE, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Mount Vernon Cancer Centre in the United Kingdom has become the first National Health Service (NHS) hospital to acquire a CyberKnife® Robotic Radiosurgery System.

The NHS has grown to become the world's largest publicly funded health service. The system was born just over 60 years ago out of a long-held ideal that quality healthcare should be available to all, regardless of wealth – and that principle remains at its core. The NHS remains free at the point of use for anyone who is a resident in the United Kingdom – more than 60 million people – with only a few minor exceptions, and is funded centrally from national taxation.

"Patients have been very eager to see CyberKnife radiosurgery available through the National Health Service, so we are excited to soon be able to offer them this state-of-the-art form of cancer care," said  Dr. Peter Ostler, Consultant Clinical Oncologist and the Trust's Clinical Chair for Cancer Services. "The CyberKnife System will enable us to expand our radiation offerings to patients who may not have been able to tolerate other treatments or have medically or surgically inoperable tumors."

The CyberKnife System uses real-time tracking capabilities to deliver high-dose radiation to tumors with pin-point accuracy, including tumors that move with respiration. As a non-invasive treatment for cancerous and non-cancerous tumors, the CyberKnife System does not require the use of stabilizing frames or uncomfortable breath holding techniques, making it an easy and comfortable experience for the patient. Treatments are typically completed in one to five days and patients can resume their normal activities immediately following treatment.

"Mount Vernon Cancer Centre has a strong reputation for cancer treatment, particularly using radiation, so it is great to see their treatment arsenal strengthened with the purchase of a CyberKnife System," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "We are proud to be working with the East and North Hertfordshire NHS Trust and are very pleased with their recognition of the CyberKnife System's unique contributions in the treatment of cancer."  

East and North Hertfordshire NHS Trust manages four hospitals, including The Mount Vernon Cancer Centre. As one of the UK's top five cancer treatment centers, The Mount Vernon Cancer Centre, which is located in North-west London, provides specialist tertiary radiotherapy services, as well as a local chemotherapy service.

About the Mount Vernon Cancer Centre

The Mount Vernon Cancer Centre, managed by the East and North Hertfordshire NHS Trust, has been based in Northwood, North-west London for many years and is a leading cancer center, treating around 5,000 new patients per annum. More than 3,000 new patients a year are treated with radiotherapy, with an additional 1,500 receiving chemotherapy (mainly from people living closer to the cancer center). It serves a population of two million people living in North-west London, Hertfordshire and parts of the Thames Valley.  

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 80,000 patients worldwide and currently more than 190 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on February 4, 2010 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

SOURCE Accuray



SOURCE Accuray
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intermountain Healthcare Selects Craneware Revenue Integrity Solutions
2. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
3. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
4. Faced With Federal Prosecution, MountainView Agrees to Stop Harassment of RNs in Settlement With Labor Board
5. Intermountain McKay-Dee Hospital Center Expands Real-Time Locating Solution From Versus Technology, Inc.
6. US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
7. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
8. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
9. Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care
10. Launch of Ipsens Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
11. Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  PTS Diagnostics, the U.S.-based manufacturer ... analyzers, A1CNow ® systems, and PTS Detect™ ... of patents that will propel the company into the ... Europe . The technology is a ... those on smartphones and tablets, and uses test strip ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), ... present live at on December 3, 2015. ... TIME: 3:15p.m. ET LINK: ... LINK: --> ... event where investors are invited to ask the company questions ...
(Date:11/30/2015)... LAKE CITY , Nov. 30, 2015 Booth ... (NYSE: VAR ) will exhibit a broader array of ... of the Radiological Society of North America ... Varian exhibit at the meeting will feature X-ray components "At ... CT tube, a line of products from Varian,s Claymount brand, ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... at a University of Delaware Accounting and Management of Information Systems course. Based ... for mid-market businesses. Sommer will speak at before student in the Enterprise Resource ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... A ... 15th annual Regional Biotech Conference, organized by the Baruch S. Blumberg Institute. , The ... 100 of the area’s life science and biotechnology leaders for the conference, which focused ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced ... its hemorrhoid ointment to its website. , “Our goal is simple:” says Michael ... hemorrhoids. Adding the comparison chart and ingredient list allows our customers to quickly ...
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad , Chili ... maximize recovery through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, ... sleep. ChiliPad precisely regulates the surface temperature of each side of the bed ...
Breaking Medicine News(10 mins):